Julius Clinical completed the merger with P95.

Julius Clinical, a global therapeutically specialized CRO, completed the merger with P95, a global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases. Financial terms were not disclosed. “P95 and Julius Clinical share a deep scientific foundation and a mission to improve global health. As the CEO of the combined organizations, I am fully committed to the exceptional teams, cultures, and partners that have driven both companies’ success. I am honored to carry these two organizations forward together as we continue to deliver unmatched high-quality, science-led research across the full development lifecycle—supporting innovation that improves lives worldwide,” Bassem Saleh, M.D., Julius Clinical CEO.